Kiniksa Pharmaceuticals International, plc (KNSA): Shareholders' Equity
$567.61M
As of 2025-12-31
$605.69M
As of 2026-03-31
+12.7%
3-year compound annual growth
+12.7%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $567.61M | +29.5% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $438.44M | -0.1% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $438.84M | +10.8% | 2026-02-24, Balance as of period end |
| 2022-12-31 | $396.15M | +114.1% | 2025-02-25, Balance as of period end |
| 2021-12-31 | $185.04M | -40.7% | 2024-02-28, Balance as of period end |
| 2020-12-31 | $311.94M | +38.4% | 2023-03-02, Balance as of period end |
| 2019-12-31 | $225.42M | -19.3% | 2022-02-24, Balance as of period end |
| 2018-12-31 | $279.27M | n/m | 2021-02-25, Balance as of period end |
| 2017-12-31 | -$89.71M | n/a | 2019-03-12, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $567.61M | +29.5% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$80.00M | n/m |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $1.06B | +2.5% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $88.30M | +54.9% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $788.80M | +7.7% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $693.11M | -11.0% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $522.60M | +8.2% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $648.02M | +191.4% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $1.27B | -7.1% |
Compare KNSA, RARE, SUPN, AXSM side by side · Screen every company in Pharmaceutical Preparations ↗